Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $24.8 million.

  • Revolution Medicines' Cash from Investing Activities rose 215.74% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$349.7 million, marking a year-over-year increase of 35.46%. This contributed to the annual value of -$554.4 million for FY2024, which is 61.82% down from last year.
  • Revolution Medicines' Cash from Investing Activities amounted to $24.8 million in Q3 2025, which was down 27.50% from $34.3 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Cash from Investing Activities ranged from a high of $107.9 million in Q2 2024 and a low of -$392.9 million during Q4 2024.
  • In the last 3 years, Revolution Medicines' Cash from Investing Activities had a median value of -$15.9 million in 2025 and averaged -$77.6 million.
  • Per our database at Business Quant, Revolution Medicines' Cash from Investing Activities spiked by 1,806.67% in 2022 and then tumbled by 6,305.36% in 2024.
  • Revolution Medicines' Cash from Investing Activities (Quarterly) stood at $8.5 million in 2021, then tumbled by 183.25% to -$7.1 million in 2022, then plummeted by 5,254.76% to -$380.4 million in 2023, then declined by 3.29% to -$392.9 million in 2024, then skyrocketed by 215.74% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $34.3 million for Q2 2025, and -$15.9 million during Q1 2025.